相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting
Domenico Viola et al.
LEUKEMIA (2021)
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Djordje Atanackovic et al.
LEUKEMIA (2020)
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects
Eric R. Fedyk et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S. Raab et al.
LANCET HAEMATOLOGY (2020)
Resistance Mechanisms towards CD38-Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen et al.
JOURNAL OF CLINICAL MEDICINE (2020)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
Alberto L. Horenstein et al.
FRONTIERS IN IMMUNOLOGY (2019)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin et al.
CELLS (2019)
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Amrita Y. Krishnan et al.
BLOOD (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee et al.
CELL METABOLISM (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
F. Morandi et al.
ONCOIMMUNOLOGY (2018)
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
Jayeeta Ghose et al.
ONCOIMMUNOLOGY (2018)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
The emerging roles of tumor-derived exosomes in hematological malignancies
M. Boyiadzis et al.
LEUKEMIA (2017)
Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
Federica Costa et al.
ONCOTARGET (2017)
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
J. Wen et al.
LEUKEMIA (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
Alberto L. Horenstein et al.
MOLECULAR MEDICINE (2016)
Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins
David J. Marshall et al.
MOLECULAR THERAPY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Biosensor reveals multiple sources for mitochondrial NAD+
Xiaolu A. Cambronne et al.
SCIENCE (2016)
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche
Valeria Quarona et al.
MARROW (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds
Rainer Boxhammer et al.
BLOOD (2015)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
Antonella Chillemi et al.
MOLECULAR MEDICINE (2013)
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction
P. Storti et al.
LEUKEMIA (2013)
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
Alberto L. Horenstein et al.
ONCOIMMUNOLOGY (2013)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
NAADP: A Universal Ca2+ Trigger
Andreas H. Guse et al.
SCIENCE SIGNALING (2008)
Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo
S Partida-Sánchez et al.
NATURE MEDICINE (2001)
分享论文
